Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy

Pharmacotherapy

Volumn 23, Issue 8 II, 2003, Pages

  Crawford, Jeffrey ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HODGKIN DISEASE; HUMAN; LEUKOCYTE COUNT; LUNG CANCER; MAJOR CLINICAL STUDY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; REVIEW;

EID: 0042259168     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.9.15s.32889     Document Type: Review

References (20)

1. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002;62(suppl 1):1-15.
2. Lyman GH, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998;34:1857-64.
3. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996;88:1907-29.
4. Amgen Inc. Neupogen (filgrastim) prescribing information. Thousand Oaks, CA; 2001.
5. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70.
6. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-24.
7. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992;80:1430-6.
8. Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001;22:405-17.
9. Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J Pharm Pharm Sci 2000;3:125-36.
10. Crawford J. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia. Drugs 2002;62(suppl 1):89-98.
11. Zamboni WC. Pharmacokinetics of pegfilgrastim. Pharmacotherapy 2003;23(8 pt 2):9S-14.
12. Molineux G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003;23(8 pt 2):3S-8.
13. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522-8.
14. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002;13:903-9.
15. Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003;21:514-19.
16. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31.
17. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35.
18. Meza L, Hackett J, Neumann T. Time to absolute neutrophil count (ANC) recovery following filgrastim in patients with breast cancer. Presented at the annual meeting of the American College of Clinical Pharmacy, Albuquerque, NM, October 20-23, 2002.
19. Amgen Inc. Neulasta (pegfilgrastim) prescribing information. Thousand Oaks, CA; 2002.
20. Meropol NJ, Miller LL, Korn EL, et al. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992;84:1201-3.